BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36698840)

  • 1. 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
    Slater K; Bosch R; Smith KF; Jahangir CA; Garcia-Mulero S; Rahman A; O'Connell F; Piulats JM; O'Neill V; Horgan N; Coupland SE; O'Sullivan J; Gallagher WM; Villanueva A; Kennedy BN
    Front Med (Lausanne); 2022; 9():1036322. PubMed ID: 36698840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
    Slater K; Heeran AB; Garcia-Mulero S; Kalirai H; Sanz-Pamplona R; Rahman A; Al-Attar N; Helmi M; O'Connell F; Bosch R; Portela A; Villanueva A; Gallagher WM; Jensen LD; Piulats JM; Coupland SE; O'Sullivan J; Kennedy BN
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.
    Tonelotto V; Costa-Garcia M; O'Reilly E; Smith KF; Slater K; Dillon ET; Pendino M; Higgins C; Sist P; Bosch R; Passamonti S; Piulats JM; Villanueva A; Tramer F; Vanella L; Carey M; Kennedy BN
    Cell Death Discov; 2024 Feb; 10(1):70. PubMed ID: 38341410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.
    Butler CT; Kennedy SA; Buckley A; Doyle R; Conroy E; Gallagher WM; O'Sullivan J; Kennedy BN
    Oncotarget; 2019 Jun; 10(38):3725-3744. PubMed ID: 31217905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Development of the Quininib Series of Ocular Drugs.
    Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
    J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
    Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
    Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
    Shu W; Zhu X; Wang K; Cherepanoff S; Conway RM; Madigan MC; Zhu H; Zhu L; Murray M; Zhou F
    Cell Oncol (Dordr); 2022 Aug; 45(4):601-619. PubMed ID: 35781872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes.
    Sundaramurthi H; Tonelotto V; Wynne K; O'Connell F; O'Reilly E; Costa-Garcia M; Kovácsházi C; Kittel A; Marcone S; Blanco A; Pallinger E; Hambalkó S; Piulats Rodriguez JM; Ferdinandy P; O'Sullivan J; Matallanas D; Jensen LD; Giricz Z; Kennedy BN
    Open Res Eur; 2023; 3():88. PubMed ID: 37981907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
    Kennedy SA; Morrissey ME; Dunne MR; O'Connell F; Butler CT; Cathcart MC; Buckley AM; Mehigan BJ; Larkin JO; McCormick P; Kennedy BN; O'Sullivan J
    BMC Cancer; 2020 Oct; 20(1):952. PubMed ID: 33008336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma.
    Benhassine M; Le-Bel G; Guérin SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
    Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
    J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
    Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
    Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target.
    Groenewoud A; Yin J; Gelmi MC; Alsafadi S; Nemati F; Decaudin D; Roman-Roman S; Kalirai H; Coupland SE; Jochemsen AG; Jager MJ; Engel FB; Snaar-Jagalska BE
    Cell Death Discov; 2023 Jun; 9(1):183. PubMed ID: 37321991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Meng Z; Chen Y; Wu W; Yan B; Zhang L; Chen H; Meng Y; Liang Y; Yao X; Luo J
    Front Immunol; 2022; 13():754645. PubMed ID: 35281030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-depth proteomic profiling of the uveal melanoma secretome.
    Angi M; Kalirai H; Prendergast S; Simpson D; Hammond DE; Madigan MC; Beynon RJ; Coupland SE
    Oncotarget; 2016 Aug; 7(31):49623-49635. PubMed ID: 27391064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma.
    Sugase T; Lam BQ; Danielson M; Terai M; Aplin AE; Gutkind JS; Sato T
    J Transl Med; 2020 May; 18(1):208. PubMed ID: 32434572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.
    Jochems A; van der Kooij MK; Fiocco M; Schouwenburg MG; Aarts MJ; van Akkooi AC; van den Berkmortel FWPJ; Blank CU; van den Eertwegh AJM; Franken MG; de Groot JB; Haanen JBAG; Hospers GAP; Koornstra RH; Kruit WHJ; Louwman M; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl MCT; van der Hoeven KJM; Kapiteijn E
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31323802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.